Correlation of the Ki67 Working Group prognostic risk categories with the Oncotype DX Recurrence Score in early breast cancer.
Rima PatelMalin HovstadiusMelanie W KierErin L MoshierBrittney S ZimmermanKrystal CascettaShabnam JafferJoseph A SparanoAmy TierstenPublished in: Cancer (2022)
In patients with early-stage, hormone receptor-positive breast cancer, decisions on adjuvant chemotherapy are based on certain biological features of the cancer and genomic assays such as the Oncotype DX Recurrence Score (RS). The goal of this study was to determine the correlation between Ki67, a marker of proliferation, and the Oncotype DX RS, a 21-gene assay demonstrated to be predictive of an adjuvant chemotherapy benefit in patients with early-stage breast cancer. In 525 patients, the authors did not find a significant correlation between Ki67 and RS.
Keyphrases
- early stage
- positive breast cancer
- early breast cancer
- end stage renal disease
- neoadjuvant chemotherapy
- ejection fraction
- newly diagnosed
- high throughput
- chronic kidney disease
- copy number
- papillary thyroid
- prognostic factors
- sentinel lymph node
- genome wide
- patient reported outcomes
- lymph node
- genome wide identification
- locally advanced
- transcription factor
- single cell
- patient reported
- genome wide analysis